Title: Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C
Abstract: HepatologyVolume 36, Issue 5 p. 1301-1302 CorrespondenceFree Access Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C Wolfgang Jessner, Wolfgang Jessner Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this authorManon Der-Petrossian, Manon Der-Petrossian Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna, Vienna, AustriaSearch for more papers by this authorLene Christiansen, Lene Christiansen Department of Clinical Biochemistry and Clinical Genetics, Odense University Hospital, Odense, DenmarkSearch for more papers by this authorHarald Maier, Harald Maier Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna, Vienna, AustriaSearch for more papers by this authorPetra Steindl-Munda, Petra Steindl-Munda Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this authorAlfred Gangl, Alfred Gangl Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this authorPeter Ferenci, Peter Ferenci Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this author Wolfgang Jessner, Wolfgang Jessner Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this authorManon Der-Petrossian, Manon Der-Petrossian Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna, Vienna, AustriaSearch for more papers by this authorLene Christiansen, Lene Christiansen Department of Clinical Biochemistry and Clinical Genetics, Odense University Hospital, Odense, DenmarkSearch for more papers by this authorHarald Maier, Harald Maier Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna, Vienna, AustriaSearch for more papers by this authorPetra Steindl-Munda, Petra Steindl-Munda Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this authorAlfred Gangl, Alfred Gangl Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this authorPeter Ferenci, Peter Ferenci Department of Internal Medicine IV, Division of Gastroenterology and HepatologySearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.35072Citations: 25AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998; 18: 67– 75. 2 Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, Caldarelli R, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322– 1326. 3 Herrero C, Vicente A, Bruguera M, Ercilla MG, Barrera JM, Vidal J, Teres J, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341: 788– 789. 4 Navas S, Bosch O, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C and B viruses infection: a retrospective study. Hepatology 1995; 21: 279– 284. 5 Stölzel U, Köstler E, Koszka C, Stöffler-Meilicke M, Schuppan D, Somasundaram R, Doss MO, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21: 1500– 1503. 6 Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alfa therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43: 529– 533. 7 Fernandez I, Castellano G, De Salamanca RE, Domingo MJ, Colina F, Fuertes A, Canga F, et al. Efficacy and safety of interferon therapy in patients with porphyria cutanea tarda (PCT) and chronic hepatitis C [Abstract]. J Hepatol 1998; 28: 190. 8 Gibson PR, Grant J, Cronin V, Blake D, Ratnaike S. Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-alfa on porphyrin profiles in plasma, urine and faeces. J Gastroenterol Hepatol 2000; 15: 192– 201. 9 Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22: 249– 250. 10 Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44: 525– 528. 11 Furata M, Kaito M, Gabazza E, Fujita N, Ishida S, Tamaki S, Ikeda R, et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 2000; 35: 60– 62. 12 Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, Mueller C, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358: 1241– 1242. 13 Christiansen L, Bygum A, Jensen A, Brandrup F, Thomsen K, Horder M, Petersen NE. Uroporphyrinogen decarboxylase gene mutations in Danish patients with porphyria cutanea tarda. Scand J Clin Lab Invest 2000; 60: 611– 616. 14 Meguro K, Fujita H, Ishida N, Akagi R, Kurihara T, Galbraith RA, Kappas A, et al. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J Invest Dermatol 1994; 102: 681– 685. 15 Whitby FG, Phillips JD, Kushner JP, Hill CP. Crystal structure of human uroporphyrinogen decarboxylase. EMBO J 1998; 17: 2463– 2471. 16 Bulaj ZJ, Philips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, Edwards CQ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95: 1565– 1571. 17 Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401– 2407. Citing Literature Volume36, Issue5November 2002Pages 1301-1302 ReferencesRelatedInformation